Developer docs
API playgroundTry for free, no card

Search company profiles

QBIC II

Full company profile

uuid0006g8p

Namestring
QBIC II
Legal namestring
Qbic Venture Partners II
Websiteurl
qbic.be
Company typeenum
Private
Founded yearint
2016
Descriptiontext

Qbic Venture Partners II (Qbic II) is the second vintage of Qbic, Belgium's inter-university venture capital platform, established in 2016 and headquartered in Zwijnaarde (Ghent). The fund invests seed and Series A capital into technology spin-offs originating from 16 Belgian knowledge partners, including major universities (UGent, VUB, KU Leuven, UHasselt, ULiège, UAntwerpen), research institutes (VIB, imec, VITO), and university hospitals (UZ Gent, UZ Brussel, UZ Antwerpen, CHU de Liège, and others). Qbic II sits within a three-fund platform (Qbic I 2012, Qbic II 2016, Qbic III 2022 — €88.5M final close) and is managed by Qbic Venture Partners II alongside Qbic III under Managing Partner Sofie Baeten.

Qbic's portfolio spans biotech (Spica Therapeutics, Animab, MRM Health, Trince, AmphiStar, Flindr Therapeutics), healthtech (Innocens, moveUP/Cascador Health), deeptech (AILOS, Swave, VoxelSensors, eyeo, Blue Foot Membranes), and software/industrial (Pleevi, Aloxy). The platform also holds a minority interest in agtech (Aphea.Bio, Rainbow Crops) and supports European Union/InvestEU-backed initiatives. Portfolio outcomes disclosed include >350 jobs created, >500 million patients potentially benefiting from innovations, and 32% female CEO representation across the Qbic II portfolio.

The business model is a conventional early-stage venture capital fund: deploying committed LP capital into equity rounds (typically leading or co-leading seed/Series A), generating returns through equity appreciation and exits, supplemented by management fees on committed capital. Qbic III is structured as an Article 8 SFDR fund promoting ESG characteristics. Distribution relies on direct relationships with the 16 knowledge-partner institutions for top-of-funnel deal flow, supplemented by industry events, LinkedIn presence, and a small direct-investment channel. Operating geographies are primarily Belgium, with portfolio companies scaling across Europe (e.g., Samsung Ventures in Swave, Qualcomm collaboration with VoxelSensors).

Short descriptiontext

Qbic Venture Partners II is a Belgian inter-university venture capital fund formed in 2016, investing seed and Series A capital into technology spin-offs originating from 16 Belgian universities, research institutes, and university hospitals across biotech, healthtech, deeptech, and software sectors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersGent, Belgium
HQ citystring
Gent
HQ countrystring
Belgium
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
seed venture capital, early-stage investment, university spin-offs, biotech venture funding, deep tech investing
Industry1 code
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)
NAICS code2 codes
  • All Other Financial Investment Activities52399
  • Other Financial Vehicles525990
SIC code1 code
  • Investment Advice6282
Product category
Venture Capital
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Fund Management
TypeLicensing Royalties
Description

Qbic generates returns through managing venture capital funds, investing in early-stage technology spin-offs from Belgian knowledge institutions. Returns are generated through equity appreciation and exits from portfolio companies.

qbic.be
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Technology or R&D, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

QBIC II is the second fund in the Qbic inter-university venture capital fund series, formed in 2016 to provide seed and early-stage equity capital to technology spin-offs and start-ups originating from Belgian knowledge institutions. The fund invests in companies commercializing research in biotech, medtech, deep tech and software, typically participating in the first external capital round. QBIC II is managed by Qbic Venture Partners II and operates alongside Qbic I and Qbic III under a multi-fund platform.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Qbic is an inter-university venture capital fund management organization managing three funds: Qbic I (2012), Qbic II (2016), and Qbic III (2022). Qbic II and Qbic III are managed by Qbic Venture Partners II and III respectively, headquartered in Belgium. The funds invest in spin-offs and start-ups from knowledge partners (Belgian universities, research institutes, hospitals). Qbic III is an Article 8 SFDR fund promoting ESG characteristics and investing in technologies impacting climate, environment, or health. The portfolio spans Biotech (Spica Therapeutics, Animab, MRM Health, Trince, AmphiStar, Flindr), HealthTech (Innocens, moveUP/Cascador Health), Deeptech (AILOS, Swave, VoxelSensors, eyeo, Blue Foot), and Software (Pleevi, Aloxy).

Product and service3 records
1Qbic I Venture Capital Fund
CategoryVenture Capital Fund
Description

The first fund in the Qbic inter-university venture capital series, formed in 2012, providing seed and early-stage equity capital to spin-offs and start-ups from Qbic's knowledge partner network with sustainability factors embedded in investment decisions.

2Qbic II Venture Capital Fund
CategoryVenture Capital Fund
Description

The second fund in the Qbic series, formed in 2016 and managed by Qbic Venture Partners II, providing seed and early-stage equity capital to spin-offs and start-ups commercializing technological innovations originating from Qbic's partner universities, research institutes, and hospitals across biotech, medtech, deep tech, and software sectors.

3Qbic III Venture Capital Fund
CategoryVenture Capital Fund
Description

The third Qbic fund, formed in 2022, structured as an Article 8 SFDR fund promoting ESG policies across all portfolio companies and investing in technologies with potential impact on climate, environment, or health, reaching a final closing of €88.5 million in 2023.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership21 partners
1Universiteit Gent (UGent)
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Major knowledge partner providing research-based spin-off opportunities in technology and life sciences.

qbic.be
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Knowledge partner contributing to biotech and medical technology spin-offs.

3Universiteit Hasselt
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Knowledge partner contributing to research-based spin-off opportunities.

qbic.be
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Knowledge partner contributing to life sciences and medical technology spin-offs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Knowledge partner contributing to academic spin-off opportunities.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research institute contributing to clean technology and sustainability spin-offs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

World-leading research institute in nanoelectronics and digital technologies contributing to deep tech spin-offs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Leading life sciences research institute contributing to numerous biotech spin-offs including Animab, MRM Health, and others.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

University hospital contributing to medical technology and health tech spin-offs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

University hospital contributing to medical research spin-offs.

11UZ Antwerpen
Strategic tierCoreTypeStrategic or Co-development Partner
Description

University hospital contributing to medical technology spin-offs.

qbic.be
Strategic tierCoreTypeStrategic or Co-development Partner
Description

University hospital in Wallonia contributing to health tech spin-offs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Regional hospital contributing to medical technology spin-offs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hospital contributing to medical technology spin-offs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hospital contributing to medical technology spin-offs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hospital contributing to medical technology spin-offs.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Hospital contributing to medical technology spin-offs.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Walloon health competitiveness cluster providing R&D project support to ABSCINT.

19Anacura
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Veterinary health company joining Animab as new investor.

qbic.be
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Entered exclusive distribution agreement with Animab for Nanoprotec in Europe.

21Qualcomm Technologies
Strategic tierMinorTypeStrategic or Co-development Partner
Description

VoxelSensors announced collaboration with Qualcomm Technologies for 3D perception sensors.

qbic.be
Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Listed Belgian investment company with broader buyout and growth investment activities across Europe. Comparable due to Belgian origin, deeptech/life sciences exposure, and prior professional overlap (Sofie Baeten was Managing Partner at Gimv); functions as a broader incumbent rather than a pure early-stage spin-out specialist.

TypeDirect peer
Description

imec's dedicated venture fund investing in nanoelectronics and semiconductor spin-offs. Directly comparable as a Belgian deeptech-focused early-stage fund sourcing from a single major research partner (imec), with overlapping portfolio companies such as eyeo and VoxelSensors.

TypeBroad incumbent
Description

Flemish regional investment company acting across the full risk-capital spectrum from seed to growth. Comparable as a Belgium-based institutional investor and co-investor in Qbic's portfolio rounds (e.g., Aphea.bio, Animab), with broader sector and stage mandate than Qbic's early-stage focus.

TypeDirect peer
Description

University-affiliated seed and early-stage fund associated with KU Leuven that invests in academic spin-offs. Directly comparable as a Belgian knowledge-partner-linked VC participating alongside Qbic in portfolio rounds (e.g., Aphea.bio Series B).

TypeDirect peer
Description

Belgian life sciences-focused venture capital fund investing in biotech spin-offs and early-stage therapeutics. Directly comparable due to Belgian geography, biotech specialism, and repeated co-investment with Qbic in companies like Aphea.bio and Animab.

6Volta Ventures
TypeDirect peer
Description

Belgian seed and early-stage venture capital fund focused on software and tech-enabled businesses. Comparable as a Belgium-based early-stage VC that has co-invested with Qbic in portfolio companies such as the moveUP/Cascador Health combined entity.

TypeDirect peer
Description

Belgian independent venture capital and growth equity firm with dedicated technology and life sciences funds. Comparable as a Belgium-based early-to-growth VC active in deeptech and biotech, overlapping with Qbic's sectoral focus.

TypeDirect peer
Description

Dutch deeptech venture capital firm leading Series A rounds in photonics and semiconductor-adjacent startups. Comparable due to deeptech specialism and shared syndication in Qbic portfolio companies such as eyeo.

TypeDirect peer
Description

Flemish innovation fund specializing in early biotech and life sciences investments. Comparable as a Belgian early-stage VC targeting academic and research-driven spin-offs, having co-invested with Qbic in Trince.

TypeRegional player
Description

Belgian investment fund focused on innovative life sciences companies in later-stage clinical development. Comparable in Belgian life sciences investing, though focused on later stages than Qbic's seed/Series A model; serves as adjacent rather than direct competitive overlap.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles7 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment11 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

QBIC II

Venture Capitalqbic.be

Qbic Venture Partners II is a Belgian inter-university venture capital fund formed in 2016, investing seed and Series A capital into technology spin-offs originating from 16 Belgian universities, research institutes, and university hospitals across biotech, healthtech, deeptech, and software sectors.

What QBIC II does

Qbic Venture Partners II (Qbic II) is the second vintage of Qbic, Belgium's inter-university venture capital platform, established in 2016 and headquartered in Zwijnaarde (Ghent). The fund invests seed and Series A capital into technology spin-offs originating from 16 Belgian knowledge partners, including major universities (UGent, VUB, KU Leuven, UHasselt, ULiège, UAntwerpen), research institutes (VIB, imec, VITO), and university hospitals (UZ Gent, UZ Brussel, UZ Antwerpen, CHU de Liège, and others). Qbic II sits within a three-fund platform (Qbic I 2012, Qbic II 2016, Qbic III 2022 — €88.5M final close) and is managed by Qbic Venture Partners II alongside Qbic III under Managing Partner Sofie Baeten.

Qbic's portfolio spans biotech (Spica Therapeutics, Animab, MRM Health, Trince, AmphiStar, Flindr Therapeutics), healthtech (Innocens, moveUP/Cascador Health), deeptech (AILOS, Swave, VoxelSensors, eyeo, Blue Foot Membranes), and software/industrial (Pleevi, Aloxy). The platform also holds a minority interest in agtech (Aphea.Bio, Rainbow Crops) and supports European Union/InvestEU-backed initiatives. Portfolio outcomes disclosed include >350 jobs created, >500 million patients potentially benefiting from innovations, and 32% female CEO representation across the Qbic II portfolio.

The business model is a conventional early-stage venture capital fund: deploying committed LP capital into equity rounds (typically leading or co-leading seed/Series A), generating returns through equity appreciation and exits, supplemented by management fees on committed capital. Qbic III is structured as an Article 8 SFDR fund promoting ESG characteristics. Distribution relies on direct relationships with the 16 knowledge-partner institutions for top-of-funnel deal flow, supplemented by industry events, LinkedIn presence, and a small direct-investment channel. Operating geographies are primarily Belgium, with portfolio companies scaling across Europe (e.g., Samsung Ventures in Swave, Qualcomm collaboration with VoxelSensors).

QBIC II firmographics

Firmographics
Name
QBIC II
Legal name
Qbic Venture Partners II
Website
https://qbic.be
Company type
Private
Founded year
2016
Operating status
Operating
Headcount range
1–10 employees
Short description
Qbic Venture Partners II is a Belgian inter-university venture capital fund formed in 2016, investing seed and Series A capital into technology spin-offs originating from 16 Belgian universities, research institutes, and university hospitals across biotech, healthtech, deeptech, and software sectors.
Ownership category
akta.pro rank

QBIC II industry classification

Industry
Product category
Venture Capital
NAICS
All Other Financial Investment Activities (52399), Other Financial Vehicles (525990)
SIC
Investment Advice (6282)
akta.pro industry
PRIMARYFSANAAAB
Early-Stage Venture Capital (Series A/B)

Keywords

  • Seed venture capital
  • Early-stage investment
  • University spin-offs
  • Biotech venture funding
  • Deep tech investing

Where QBIC II is headquartered

Location

Headquarters

HQ city
Gent
HQ country
Belgium
HQ region
Europe

Offices2 records

Markets served

QBIC II business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Others

Revenue model

  1. Fund Management: Qbic generates returns through managing venture capital funds, investing in early-stage technology spin-offs from Belgian knowledge institutions. Returns are generated through equity appreciation and exits from portfolio companies.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

QBIC II product offering

Product offering

Core offering

QBIC II is the second fund in the Qbic inter-university venture capital fund series, formed in 2016 to provide seed and early-stage equity capital to technology spin-offs and start-ups originating from Belgian knowledge institutions. The fund invests in companies commercializing research in biotech, medtech, deep tech and software, typically participating in the first external capital round. QBIC II is managed by Qbic Venture Partners II and operates alongside Qbic I and Qbic III under a multi-fund platform.

Product overview

Qbic is an inter-university venture capital fund management organization managing three funds: Qbic I (2012), Qbic II (2016), and Qbic III (2022). Qbic II and Qbic III are managed by Qbic Venture Partners II and III respectively, headquartered in Belgium. The funds invest in spin-offs and start-ups from knowledge partners (Belgian universities, research institutes, hospitals). Qbic III is an Article 8 SFDR fund promoting ESG characteristics and investing in technologies impacting climate, environment, or health. The portfolio spans Biotech (Spica Therapeutics, Animab, MRM Health, Trince, AmphiStar, Flindr), HealthTech (Innocens, moveUP/Cascador Health), Deeptech (AILOS, Swave, VoxelSensors, eyeo, Blue Foot), and Software (Pleevi, Aloxy).

Differentiator

Problem solved

Functional benefit

Products and services

  • Qbic I Venture Capital Fund The first fund in the Qbic inter-university venture capital series, formed in 2012, providing seed and early-stage equity capital to spin-offs and start-ups from Qbic's knowledge partner network with sustainability factors embedded in investment decisions.
  • Qbic II Venture Capital Fund The second fund in the Qbic series, formed in 2016 and managed by Qbic Venture Partners II, providing seed and early-stage equity capital to spin-offs and start-ups commercializing technological innovations originating from Qbic's partner universities, research institutes, and hospitals across biotech, medtech, deep tech, and software sectors.
  • Qbic III Venture Capital Fund The third Qbic fund, formed in 2022, structured as an Article 8 SFDR fund promoting ESG policies across all portfolio companies and investing in technologies with potential impact on climate, environment, or health, reaching a final closing of €88.5 million in 2023.

Companies that use QBIC II

Customer profile

Segments2 records

Ideal customer profiles2 records

QBIC II technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

QBIC II partnerships and signals

Strategic signal

Partnerships

21 partnerships are on record, tiered core and minor.

  • Universiteit Gent (UGent)coreStrategic or Co-development PartnerMajor knowledge partner providing research-based spin-off opportunities in technology and life sciences.
  • VUB (Vrije Universiteit Brussel)coreStrategic or Co-development PartnerKnowledge partner contributing to biotech and medical technology spin-offs.
  • Universiteit HasseltcoreStrategic or Co-development PartnerKnowledge partner contributing to research-based spin-off opportunities.
  • ULiège (Université de Liège)coreStrategic or Co-development PartnerKnowledge partner contributing to life sciences and medical technology spin-offs.
  • Universiteit AntwerpencoreStrategic or Co-development PartnerKnowledge partner contributing to academic spin-off opportunities.
  • VITOcoreStrategic or Co-development PartnerResearch institute contributing to clean technology and sustainability spin-offs.
  • imeccoreStrategic or Co-development PartnerWorld-leading research institute in nanoelectronics and digital technologies contributing to deep tech spin-offs.
  • VIB (Vlaams Instituut voor Biotechnologie)coreStrategic or Co-development PartnerLeading life sciences research institute contributing to numerous biotech spin-offs including Animab, MRM Health, and others.
  • UZ GentcoreStrategic or Co-development PartnerUniversity hospital contributing to medical technology and health tech spin-offs.
  • UZ BrusselcoreStrategic or Co-development PartnerUniversity hospital contributing to medical research spin-offs.
  • UZ AntwerpencoreStrategic or Co-development PartnerUniversity hospital contributing to medical technology spin-offs.
  • CHU de LiègecoreStrategic or Co-development PartnerUniversity hospital in Wallonia contributing to health tech spin-offs.
  • Ziekenhuis Oost-Limburg GenkcoreStrategic or Co-development PartnerRegional hospital contributing to medical technology spin-offs.
  • AZ Maria MiddelarescoreStrategic or Co-development PartnerHospital contributing to medical technology spin-offs.
  • OLV AalstcoreStrategic or Co-development PartnerHospital contributing to medical technology spin-offs.
  • VITAZcoreStrategic or Co-development PartnerHospital contributing to medical technology spin-offs.
  • Clinique Saint-Luc BougecoreStrategic or Co-development PartnerHospital contributing to medical technology spin-offs.
  • BioWinminorStrategic or Co-development PartnerWalloon health competitiveness cluster providing R&D project support to ABSCINT.
  • AnacuraminorStrategic or Co-development PartnerVeterinary health company joining Animab as new investor.
  • HuvepharmaminorChannel Partner/ Reseller/ DistributorEntered exclusive distribution agreement with Animab for Nanoprotec in Europe.
  • Qualcomm TechnologiesminorStrategic or Co-development PartnerVoxelSensors announced collaboration with Qualcomm Technologies for 3D perception sensors.

Scale indicators6 records

Recent moves7 records

Expansion highlights6 records

QBIC II competitors and assessment

Company assessment

Broad incumbents

  • Gimv: Listed Belgian investment company with broader buyout and growth investment activities across Europe. Comparable due to Belgian origin, deeptech/life sciences exposure, and prior professional overlap (Sofie Baeten was Managing Partner at Gimv); functions as a broader incumbent rather than a pure early-stage spin-out specialist.
  • PMV (Participatie Maatschappij Vlaanderen): Flemish regional investment company acting across the full risk-capital spectrum from seed to growth. Comparable as a Belgium-based institutional investor and co-investor in Qbic's portfolio rounds (e.g., Aphea.bio, Animab), with broader sector and stage mandate than Qbic's early-stage focus.

Direct peers

  • imec.xpand: imec's dedicated venture fund investing in nanoelectronics and semiconductor spin-offs. Directly comparable as a Belgian deeptech-focused early-stage fund sourcing from a single major research partner (imec), with overlapping portfolio companies such as eyeo and VoxelSensors.
  • Gemma Frisius Fund: University-affiliated seed and early-stage fund associated with KU Leuven that invests in academic spin-offs. Directly comparable as a Belgian knowledge-partner-linked VC participating alongside Qbic in portfolio rounds (e.g., Aphea.bio Series B).
  • V-Bio Ventures: Belgian life sciences-focused venture capital fund investing in biotech spin-offs and early-stage therapeutics. Directly comparable due to Belgian geography, biotech specialism, and repeated co-investment with Qbic in companies like Aphea.bio and Animab.
  • Volta Ventures: Belgian seed and early-stage venture capital fund focused on software and tech-enabled businesses. Comparable as a Belgium-based early-stage VC that has co-invested with Qbic in portfolio companies such as the moveUP/Cascador Health combined entity.
  • Capricorn Partners: Belgian independent venture capital and growth equity firm with dedicated technology and life sciences funds. Comparable as a Belgium-based early-to-growth VC active in deeptech and biotech, overlapping with Qbic's sectoral focus.
  • Innovation Industries: Dutch deeptech venture capital firm leading Series A rounds in photonics and semiconductor-adjacent startups. Comparable due to deeptech specialism and shared syndication in Qbic portfolio companies such as eyeo.
  • Novalis II (Flanders Innovation Fund): Flemish innovation fund specializing in early biotech and life sciences investments. Comparable as a Belgian early-stage VC targeting academic and research-driven spin-offs, having co-invested with Qbic in Trince.

Regional players

  • Fund+: Belgian investment fund focused on innovative life sciences companies in later-stage clinical development. Comparable in Belgian life sciences investing, though focused on later stages than Qbic's seed/Series A model; serves as adjacent rather than direct competitive overlap.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

QBIC II social profiles

Digital presence

QBIC II financial estimates

Financial estimate

Revenue estimate

Valuation estimate

QBIC II leadership team

Management profile

Number of profiles

Profiles7 records

QBIC II funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

QBIC II M&A and investment

M&A and investment

M&A

Investments11 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about QBIC II

What does QBIC II do?

QBIC II is the second fund in the Qbic inter-university venture capital fund series, formed in 2016 to provide seed and early-stage equity capital to technology spin-offs and start-ups originating from Belgian knowledge institutions. The fund invests in companies commercializing research in biotech, medtech, deep tech and software, typically participating in the first external capital round. QBIC II is managed by Qbic Venture Partners II and operates alongside Qbic I and Qbic III under a multi-fund platform.

Is QBIC II a public or private company?

QBIC II is a private company. It is classified as private equity controlled and is currently operating.

When was QBIC II founded?

QBIC II was founded in 2016. It employs 1 to 10 people.

Where is QBIC II based?

QBIC II is headquartered in Gent, Belgium, in the Europe region.

How does QBIC II make money?

One revenue line is on record: fund Management.

Who are QBIC II's main competitors?

Broad incumbents on record are Gimv and PMV (Participatie Maatschappij Vlaanderen). Direct peers are imec.xpand, Gemma Frisius Fund, V-Bio Ventures, Volta Ventures, Capricorn Partners, Innovation Industries and Novalis II (Flanders Innovation Fund). Fund+ is listed as a regional player.

Does QBIC II have an API?

No public API is recorded for QBIC II.

What industry is QBIC II in?

QBIC II's product category is Venture Capital. Its primary akta.pro industry code is FSANAAAB, Early-Stage Venture Capital (Series A/B). Its NAICS code is 52399 and its SIC code is 6282.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
AETOSWireMRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcer...MRM Health's lead candidate MH002 received FDA Fast Track designation for mild-to-moderate ulcerative colitis. The designation follows a Phase 2a trial showing excellent safety and encouraging efficacy signals. A Phase 2b study (STARFISH-UC) is planned, with first results expected in Q4 2027.Business Wire BlogMRM Health’s Lead Candidate MH002 Granted Fast Track Designation by U.S. FDA for the Treatment of Mild-to-Moderate Ulcerative ColitisThe U.S. FDA granted Fast Track designation to MRM Health's MH002 for mild-to-moderate ulcerative colitis. The designation follows Phase 2a results showing excellent safety and encouraging efficacy signals. MH002 will be evaluated in a Phase 2b study with first results expected in Q4 2027.QbicQbicAnimab closed a EUR 10 million Series B round led by AIF, PMV, and QBIC III to support commercialization of Nanoprotec in Europe. The oral antibody targets ETEC F4 in piglets, with an EMA submission planned by end of 2025 and market launch by end of 2026.Tech.euBelgian HXR platform Swave picks up €7 million to bring the metaverse to lifeBelgium-based Swave Photonics has raised €7 million in funding to commercialize its holographic eXtended Reality (HXR) technology for the metaverse. The investment round was co-led by imec.xpand and Flanders Future Techfund, with backing from QBIC, to support the development of gigapixel displays viewable without headsets.FinSMEsQbic Holds First Close of New Fund, at EUR 49MQbic, a Belgian inter-university venture capital firm, closed its third fund at EUR 49M. The fund invests in spin-offs from partner universities and research institutes, with a pipeline of 100 projects annually. It expects to review an average of 100 potential projects annually.